Actinium Pharmaceuticals, Inc. Investors Urged to Seek Guidance Amid Securities Class Action Deadline Approaching

Friday 28th of March 2025 21:09:00

ROSEN A LEADING LAW FIRM ENCOURAGES ACTINIUM PHARMACEUTICALS INC INVESTORS TO SECURE COUNSEL BEFORE DEADLINE IN ONGOING INVESTIGATION

New York, NY - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Actinium Pharmaceuticals Inc. (NYSE: ATNM) securities between January 10, 2019 and February 24, 2023, both dates inclusive, of the important February 26, 2023 lead plaintiff deadline in the ongoing federal securities class action commenced by the firm.

The lawsuit alleges that Actinium Pharmaceuticals Inc. made false and misleading statements to the investing public during the class period. On February 24, 2023, the Company disclosed that it had received a written notice from the FDA stating that the Company's Investigational New Drug (IND) application for its lead product candidate, AC- 130, had been placed on clinical hold. The Company's shares declined significantly on this news.

A class action has been filed on behalf of all persons who purchased Actinium Pharmaceuticals Inc. securities between January 10, 2019 and February 24, 2023, both dates inclusive. The lawsuit seeks to recover damages for Actinium Pharmaceuticals Inc. investors under the federal securities laws.

If you purchased Actinium Pharmaceuticals Inc. securities during the class period and would like to join the action, please contact a Rosen Law Firm representative at 434-736-0200, toll-free, or via email at info@rosenlegal.com.

A case is not certified for hearing or trial until a judge decides there is sufficient evidence of alleged wrongdoing to warrant further action. Any potential claims against Actinium Pharmaceuticals Inc. must be brought within three years from the original date of the complaint. Rosen Law Firm encourages investors to secure counsel before the deadline.